The change to open listing on the NL Prescription Drug Program reduces the administrative burden of prescribers by eliminating the special authorization process that had been in place.
Government is expanding prescription coverage for long-acting muscarinic antagonist (LAMAs) inhalers, used in the treatment of Chronic Obstructive Pulmonary Disease. The change to open listing on the NL Prescription Drug Program reduces the administrative burden of prescribers by eliminating the special authorization process that had been in place. This will ensure NLPDP beneficiaries have timely access to these inhalers for the treatment of their COPD.
Corner Brook RNC looking to arrest 44-year-old Robert Gould
RNC say the fire that levelled a home and shed in Frenchman's Cove was not suspicious
Bay of Islands Volunteer Search and Rescue offers tips on wilderness travel
Indigenous Craft fair at Grenfell Campus this Sunday, 25 tables on display
Government signs MOU with Indigenous groups on healthcare
